A
691.40
-1.43 (-0.21%)
| Penutupan Terdahulu | 692.83 |
| Buka | 695.32 |
| Jumlah Dagangan | 418,799 |
| Purata Dagangan (3B) | 363,113 |
| Modal Pasaran | 42,910,281,728 |
| Harga / Pendapatan (P/E TTM) | 35.33 |
| Harga / Pendapatan (P/E Ke hadapan) | 25.13 |
| Harga / Jualan (P/S) | 10.56 |
| Harga / Buku (P/B) | 5.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | 40.26% |
| Margin Operasi (TTM) | 17.50% |
| EPS Cair (TTM) | 16.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 95.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.71% |
| Nisbah Semasa (MRQ) | 7.29 |
| Aliran Tunai Operasi (OCF TTM) | -82.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.39 M |
| Pulangan Atas Aset (ROA TTM) | -0.21% |
| Pulangan Atas Ekuiti (ROE TTM) | 17.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | argenx SE | Menurun | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 55.54% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bellevue Group Ag | 31 Dec 2025 | 461,854 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1,247.00 (Wells Fargo, 80.36%) | Beli |
| Median | 1,000.00 (44.63%) | |
| Rendah | 867.00 (Baird, 25.40%) | Pegang |
| Purata | 1,014.33 (46.71%) | |
| Jumlah | 8 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 770.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 09 Mar 2026 | 1,000.00 (44.63%) | Beli | 740.40 |
| 14 Jan 2026 | 1,000.00 (44.63%) | Beli | 799.33 | |
| Baird | 27 Feb 2026 | 867.00 (25.40%) | Pegang | 766.92 |
| Citizens | 27 Feb 2026 | 944.00 (36.53%) | Beli | 766.92 |
| Guggenheim | 27 Feb 2026 | 1,120.00 (61.99%) | Beli | 766.92 |
| HC Wainwright & Co. | 27 Feb 2026 | 940.00 (35.96%) | Beli | 766.92 |
| RBC Capital | 27 Feb 2026 | 890.00 (28.72%) | Beli | 766.92 |
| Wells Fargo | 27 Feb 2026 | 1,247.00 (80.36%) | Beli | 766.92 |
| 20 Jan 2026 | 1,317.00 (90.48%) | Beli | 809.64 | |
| Citigroup | 08 Jan 2026 | 1,091.00 (57.80%) | Beli | 795.57 |
| Truist Securities | 08 Jan 2026 | 1,030.00 (48.97%) | Beli | 795.57 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG |
| 12 Jan 2026 | Pengumuman | argenx Highlights 2026 Strategic Priorities |
| 06 Jan 2026 | Pengumuman | argenx to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | argenx Announces Leadership Transition Marking Next Evolution of Growth |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |